Emerging nanoformulation strategies for phytocompounds and applications from drug delivery to phototherapy to imaging

Hwa Seung Han\textsuperscript{a}, Song Yi Koo\textsuperscript{a}, Ki Young Choi\textsuperscript{a,\textsuperscript{b},\textsuperscript{c}}

\textsuperscript{a} Natural Product Informatics Research Center, Korea Institute of Science and Technology (KIST), Gangneung, 25451, Republic of Korea
\textsuperscript{b} Division of Bio-Medical Science and Technology, KIST School, University of Science and Technology (UST), Seoul, 02792, Republic of Korea

**ABSTRACT**

Over thousands of years, natural bioactive compounds derived from plants (bioactive phytocompounds, BPCs) have been used worldwide to address human health issues. Today, they are an important source for drug discovery in the development of modern medicines. Although many BPCs have promising biological activities, most of them cannot be effectively utilized in drugs for therapeutic applications because of their inherent limitations of low solubility, structural instability, short half-life, poor bioavailability, and non-specific distribution to organs. Researchers have utilized emerging nanoformulation (NF) technologies to overcome these limitations as they have demonstrated great potential to improve the solubility, stability, and pharmacokinetic and pharmacodynamic characteristics of BPCs. This review exemplifies NF strategies for resolving the issues associated with BPCs and summarizes recent advances in their preclinical and clinical applications for imaging and therapy. This review also highlights how innovative NF technologies play a leading role in next-generation BPC-based drug development for extended therapeutic applications. Finally, this review discusses the opportunities to take BPCs with meaningful clinical impact from bench to bedside and extend the patent life of BPC-based medicines with new formulations or application to new adjacent diseases beyond the primary drug indications.

**Keywords:** Natural products, Phytocompound, Nanoformulation, Drug delivery, Phototherapy

1. Introduction

Throughout human history, natural products have been an invaluable resource as therapeutics for diseases \cite{1-3}. Since the first written records on the medicinal applications of approximately 1000 plants in Mesopotamia in 2600 BCE, there has been an exponential growth in natural product-based research for medicinal uses \cite{4}. A wide variety of natural products originate from diverse natural resources, such as plants, bacteria, fungi, and marine organisms. Among them, plants are a crucial source of pharmacologically active compounds, including many plant-derived blockbuster drugs, such as paclitaxel, morphine, and artemisinin. Currently, over 100 active phytochemicals are used for medicinal purposes, and almost 80\% of the world’s population depends on plant-derived extracts for primary health care \cite{5,6}.

Phytochemicals with various molecular sizes, chemotypes, and structural features have been collected in the form of extracts, fractions, or bioactive compounds through purification processes \cite{7}. Among the rest, the bioactive compounds, referred to as bioactive phytocompounds (BPCs) in this Review, are in turn isolated from the bioactive fractions by bioassay-guided purification. Although many reports have demonstrated promising biological activities of various extracts and fractions, there is consensus that identifying and isolating BPCs by their biological activities is imperative for the use of phytochemicals as safe and effective phytomedicines \cite{8,9}.

In many studies, BPCs have shown promising anticancer, anti-inflammatory, antioxidant, antibacterial, and anti-neurodegenerative effects for treating or preventing several diseases (Fig. 1) \cite{10-13}. Many bioactive compounds have been evaluated in clinical studies and are currently prescribed clinically (Table 1).

For instance, the US Food and Drug Administration (FDA) approved vinblastine for breast cancer in 1965 and paclitaxel (Taxol®) for ovarian cancer in 1992. Since then, many BPCs have been approved. Accordingly, phytochemicals and their derivatives currently account for approximately one-third of the drugs approved by the FDA \cite{3,14}. However, the clinical use of BPCs has often been hampered by their poor solubility, bioavailability, and stability \cite{15-17}. These inherent limitations of BPCs have led to critical issues in clinical studies, including insufficient intravenous dosing, reduced biological action in...
physiological conditions, and deficient plasma levels of administered BPC families, such as polyphenols, alkaloids, and flavonoids [18–21]. For this reason, the number of new BPC-based drug approvals has remained stationary despite the increasing expenditure and quantity of scientific reports published [22,23].

To overcome the drawbacks of BPC-based therapeutics, researchers from multidisciplinary research fields, such as pharmacology, materials sciences, and nanoscience, have begun utilizing nanoformulation (NF) techniques to encapsulate BPCs. NFs based on nanocarriers composed of lipids, proteins, polymers, and polysaccharides have shown great promise in overcoming the inherent drawbacks of BPCs [24–28]. Owing to their unique physicochemical properties, such as the large surface area to volume ratio, high reactivity, and tissue-specific distribution, nanocarriers can alter the physico-biochemical properties of BPCs and increase their therapeutic efficacy for human diseases.

Several BPC-based nanoformulations (BPC-NFs) have been approved for clinical use by the FDA and are prescribed clinically. Examples include liposomal vincristine for acute lymphoid leukemia (Marqibo®), paclitaxel-bound albumin (Abraxane®), and paclitaxel-loaded polyethylene glycol-polyactic acid (PEG-PLA) polymeric micelle (Genexol-PM®) for breast and lung cancer (Table 2). Many other BPC-NFs are also currently under clinical trials. The enormous potential of BPC-NFs is evident from the publication trends over the last decade (Fig. 2). Since the first report of a nano-sized liposomal formulation in 1985, over 3000 publications on BPC-NFs had been published as of 2019. Among them, NFs based on nanoparticles, nanoemulsions, or lipid-based nanocarriers other than studies on liposomal BPC-NFs account for almost one-third. The remainder are BPC-liposomes, such as solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs). Nanoparticle-based BPC-NFs have been studied since 1997. The number of publications on NFs has steeply increased recently, outnumbering the publications on liposome-based BPC-NFs from 2007, totaling 1876 by 2019. Other types of BPC-NFs have also been widely studied and published in almost 900 articles as of 2019. Publication trends indicate the growing research interest in BPC-NFs and changes in NF technology for BPCs.

The following sections review recent biomedical applications of BPC-NFs from targeted drug delivery to imaging to phototherapy. This review particularly focuses on NF strategies to resolve the inherent limitations of phytochemical BPC drugs. The role of innovative NF technologies in next-generation phytochemical-based drug development for extended therapeutic applications is also discussed.

2. Structural design of nanoformulations

The main goal in designing NFs is to manage particle size, surface properties, and release profiles of bioactive compounds to accomplish the site-specific accumulation and action of the drugs at the therapeutically optimal rate and dose regimen. To improve the properties of bioactive compounds, NFs, typically 10–200 nm in diameter, are synthesized through encapsulation, i.e., entrapment of drugs inside the nanocarriers, or complexation, i.e., covalent attachment of drug molecules to nanocarriers. Such NFs have been employed in drug delivery research to improve the bioavailability, solubility, prolonged blood circulation, and targeted delivery of drugs while minimizing their side effects. NFs can enter the body via inhalation, ingestion, skin penetration, or injection and potentially interact with biological systems [29]. NF design helps increase the possibility of reaching the site of action after administration, protecting the cargo from environmental factors such as pH, enzymes, and biochemical degradation. Moreover, NFs can lower administration doses by targeted delivery, site-specific release, and in turn, improved therapeutic effects of drugs [30]. On the other hand, the NFs can be designed to be responsive to exogenous stimuli (e.g., temperature, light, magnetic/electric field, and ultrasound) or endogenous stimuli (e.g., changes in pH, redox potential, and concentration of enzymes). BPC release from the stimuli-responsive NFs can be
controlled by specific environmental conditions or external energy input [31–36].

Based on these advantages, NF approaches have shown great potential to improve the pharmacokinetic and pharmacodynamic properties of BPCs and help overcome their inherent limitations by enhancing their solubility, bioavailability, stability, and targeted delivery [37–39]. The diverse methods for the preparation of BPC-NFs can be applied by their solubility, bioavailability, stability, and targeted delivery [37–39]. The diverse methods for the preparation of BPC-NFs can be applied by their solubility, bioavailability, stability, and targeted delivery [37–39]. The diverse methods for the preparation of BPC-NFs can be applied by their solubility, bioavailability, stability, and targeted delivery [37–39].

### Table 1

Characteristics of bioactive phytocompounds and their clinical statuses.

| Natural compound            | Natural resource                  | Solubility (log P) | Biological activity                  | Status       |
|-----------------------------|-----------------------------------|--------------------|--------------------------------------|--------------|
| Artemisinin                 | Artemisia annua                   | 3.11               | Anticancer                           | Phase 3      |
| Catechin                    | Green tea, beans                  | 1.80               | Antioxidant                          | Phase 4      |
| Caffeic acid                | Coffee, Eucalyptus                | 1.53               | Anticancer, antioxidant, anti-inflammatory | Phase 3 |
| Camptothecin                | Stem wood of the Chinese tree     | 1.74               | Anticancer                           | Phase 1      |
| Combretastatin              | Bark of Combretum caffra          | 2.34               | Anticancer                           | Phase 2      |
| Curcumin                    | Tumeric                           | 4.12               | Inhibition of tumor cell proliferation, anti-inflammatory | Phase 4 |
| EGCG                        | Green tea, white tea, black tea   | 3.08               | Antioxidant, chemopreventive         | Phase 3      |
| Epicatechin                 | Woody plants                      | 1.8                | Antioxidant                          | Phase 2      |
| Genistein                   | Plants (lupins, fava beans, soybeans) | 3.08               | Anticancer, anti-inflammatory        | Phase 3      |
| Lycopene                    | tomato                            | 11.93              | Antioxidant, anticancer              | Phase 4      |
| Paclitaxel                  | Bark of Pacific yew tree          | 3.00               | Mitotic inhibitor in cancer chemotherapy | Approved (Taxol®): FDA (1998) |
| Quercetin                   | Fruits, red onions, kale          | 2.16               | Anti-inflammatory, anticancer        | Phase 3      |
| Resveratrol                 | Grapes, blueberries, raspberries, mulberries | 3.4                | Antioxidant, anti-inflammatory, anticancer | Phase 4 |
| Salvianolic acid B          | Red sage                          | 4.99               | Antioxidant, angioptegen               | Phase 2      |
| Silibinin                   | Milk thistle, coffee              | 2.63               | Hepatoprotective, anticancer         | Phase 4      |
| Sinomenine                  | Roots of Sinomenium acutum       | 1.83               | Anti-inflammatory, anti-rheumatic    | Phase 3      |
| Sulforaphane                | Brassica vegetables               | 0.22               | Anticancer, antioxidant, anti-inflammatory | Phase 2 |
| Thymoquinone                | Herbs, spices                     | 2.55               | Hepatoprotective, antioxidant, anti-inflammatory | Phase 2 |
| Ursolic acid                | Fruits (waxes of apples, pears)   | 6.58               | Antitumor, antioxidant               | Phase 2      |

* log P was obtained from ChemAxon.

** Clinical status was obtained from [http://clinicaltrials.gov](http://clinicaltrials.gov) (top clinical status in drugs of intervention category).

### Table 2

Representative clinical trials of BPC-based nanomedicine.

| Name                  | Formulation type                  | Indication a | Clinical status a |
|-----------------------|-----------------------------------|--------------|-------------------|
| Camptothecin          | PEG-drug conjugate                | Gastric cancer | Phase 2          |
|                      | Polyglutamic acid-drug conjugate  | Colon cancer, ovarian cancer | Phase 1/2 |
|                      | Cycloextrim NP                     | Solid tumors, renal cell carcinoma, rectal cancer, non-small-cell lung cancer | Phase 1/2 |
|                      | HPMA-drug conjugate                | Solid tumors | Phase 1          |
|                      | Fleximer-drug conjugate            | Gastric cancer, lung cancer | Phase 1 |
| Curcumin              | Liposome                           | Advanced cancer | Phase 1          |
|                      | Liposome                           | Metastatic pancreatic cancer | Approved: FDA (2015) |
| Paclitaxel            | NP’s albumin-bound                 | Breast cancer, non-small-cell lung cancer, pancreatic cancer | Abraxane® Approved: FDA (2005, 2012, 2013) |
|                      | Micelle                            | Ovarian cancer, primary peritoneal cancer | Approved: EMA (2018) |
|                      | PEG-PLA polymeric micelle          | Breast cancer, lung cancer | Genevex-PM® Approved: marketed in Korea and Europe (2007) |
|                      | Polymeric micelle                  | Advanced breast cancer | Phase 3 |
|                      | Polyglutamic acid-drug conjugate   | Lung cancer, ovarian cancer | Phase 3 |
|                      | DHA-drug conjugate                 | Melanoma, liver cancer, adenocarcinoma, kidney cancer, non-small-cell lung cancer | Phase 2/3 |
|                      | PEG-PAA polymeric micelle          | Gastric cancer, breast cancer | Phase 2/3 |
|                      | Liposome                           | Triple-negative breast cancer | Phase 2 |
|                      | Liposome                           | Solid tumors, gastric cancer, metastatic breast cancer | Phase 2 |
|                      | Liposome                           | Ovarian cancer, breast cancer, lung cancer | Phase 1/2 |
|                      | Polymeric NPs                      | Peritoneal neoplasms | Ovarian cancer | Phase 1 |
|                      | Polymeric micelle                  | Solid tumor | Phase 1 |
|                      | HPMA-drug conjugate                |               |                   |
| Vincristine           | Liposome                           | Acute lymphoid leukemia | Marqibo® Approved: FDA (2012) |

a Indication and clinical status were obtained from [http://clinicaltrials.gov](http://clinicaltrials.gov) (top clinical status in drugs of intervention category).

Fig. 3, this section highlights various NF platforms for BPCs, such as liposomes, SLMs, NLCs, phytosomes, nanoparticles, and nanoemulsions.

#### 2.1. Liposomes

Since Bangham et al. first reported a synthetic liposome in 1961, liposomes have offered the potential to enhance blood half-life, increase drug concentration in the target tissue and reduce the related adverse effects (e.g., cardiotoxicity) [40,41]. Liposomes, which are biodegradable and non-toxic vehicles, can encapsulate both hydrophilic and hydrophobic compounds due to the polar lipid structure of their concentric bilayer [42–44]. Liposomal NFs have several advantages, such as excellent biocompatibility, simple synthesis, encapsulation versatility...
for hydrophilic, amphiphilic, and lipophilic molecules, and prolonged circulation in the bloodstream [45-47]. Based on these characteristics, various BPCs formulated with liposomes have been studied, as summarized in Table 3.

Liposomal NFs have also been modified with functional moieties to improve their performance, such as prolonged blood circulation, target-specific delivery, and enhanced cellular penetration [45,48,49]. The representative approach is PEGylation, which is the conjugation of polyethylene glycol (PEG) molecules with NFs. The clearance of NFs by the mononuclear phagocytic system (MPS) in the bloodstream can be affected by their physicochemical properties. In particular, PEGylation impedes the clearance followed by opsonization and phagocytosis, which subsequently improves the pharmacokinetics of NFs [50-52].

PEGylated liposomes have been employed as a formulation platform in pegylated liposomal doxorubicin (Doxil®), the first clinical NF approved by the FDA for treating some types of cancers in 1995. PEGylated liposomes have also been used for the delivery of an BPC derivative, irinotecan. The FDA approved the use of pegylated liposomal irinotecan (Onivyde®) to treat metastatic pancreatic ductal adenocarcinoma in 2015. Many preclinical and clinical studies have demonstrated that pegylated liposomal formulations improve pharmacokinetics, increase drug concentration in tumor tissues, and reduce side effects.

Targeting or cell-penetrating molecules, such as antibodies, antigen-binding fragments (Fab’), peptides, and small molecules, have been further conjugated onto pegylated liposomes to construct targeted liposomes that actively bind to or penetrate target tissues or cells. In a clinical study, pegylated liposomal doxorubicin was functionalized with EGFR Fab’ to treat patients with EGFR-overexpressing advanced solid tumors that were no longer amenable to standard treatment [53]. In another study, pegylated liposomes were dual-functionalized with a tandem peptide conjugation of cell-penetrating peptide R8 and a tumor-targeting peptide cyclic RGD to bypass the blood-brain barrier (BBB), target glioma tissues, and penetrate the tumor tissue [54].

Liposomal NFs have also been engineered by changing the chemical composition of their bilayer components for drug delivery responsive to stimuli, such as enzymes, redox, and light [45,48,49]. An example is a lysolipid-based thermosensitive liposome, which showed improved bioavailability, thermoresponsiveness, and fast drug release behavior. thermoDOX®, a doxorubicin-loaded thermoresponsive liposome, is currently under Phase III clinical trials [55,56].

Recently, niosomes have been studied as drug delivery nanocarriers. Unlike liposomes consisting of double-chain phospholipids, niosomes are comprised of uncharged single-chain surfactants and cholesterol. This unique structure enables niosomes to encapsulate both hydrophobic and hydrophilic compounds within the nanostructure and improve their pharmacokinetics and organ distribution [57-59]. Niosomes are considered nanocarriers that can overcome the limitations of liposomes owing to their lower cost, improved chemical stability, and purer phospholipid contents of single-chain phospholipids over double-chain phospholipids [60,61].

2.2. Solid lipid nanoparticles and nanostructured lipid carriers

In addition to traditional liposomal formulations, diverse lipid-based nanocarriers, including SLNs and NLCs, have been developed and employed as NFs. SLNs and NLCs can be prepared reproducibly using high-pressure homogenization or high-speed stirring without the use of toxic organic solvents [62,63]. The solid matrices of SLNs and NLCs allow the entrapment of hydrophilic and hydrophobic drugs with higher entrapment efficiencies than those of liposomes, improving the stability of BPCs [64]. Furthermore, SLNs and NLCs enable controlled drug release and can be functionalized with appropriate ligands to target specific tissues [65]. Therefore, SLNs and NLCs have been widely utilized for topical, oral, intranasal, pulmonary, and parenteral applications.

SLNs are composed of a solid lipid core stabilized by surfactants in an aqueous dispersion and are considered the first generation of lipid nanoparticles with a solid matrix. SLNs have proven to be an efficient and attractive alternative to colloidal drug carriers due to their excellent biocompatibility, protective effects on labile drugs in the bloodstream or GI tract, controlled drug release, and enhanced drug absorption [65,66]. SLNs can load lipophilic and hydrophilic drug molecules, such as liposomes and niosomes. A recent report demonstrated the formulation of a BPC, baicalin, with SLNs by the coacervation separation technique based on fatty acid precipitation from stearate sodium salt micelles in the presence of polymeric nonionic surfactants [67]. The SLN carrier had a mean diameter of 347 nm (PDI: 0.169) and an entrapment efficiency of over 88%. An in vivo pharmacokinetic study showed that baicalin-loaded SLN carriers increase oral absorption compared with a baicalin suspension, improving the bioavailability of baicalin following oral administration.

However, these systems generally show a low drug payload capacity and risk drug expulsion while in storage [68]. NLCs, the second generation of lipid particles, have been developed to address these issues. NLCs are composed of a mixture of solid and liquid lipids. Incorporating a liquid lipid into a solid matrix increases imperfections in the solid matrix core, leading to unique nanostructures with improved drug incorporation and sustained release properties compared to those of SLNs [64,69]. For example, an BPC, oxyresveratrol, was formulated in NLCs and SLNs via a high-shear homogenization technique to improve its oral bioavailability [70]. The oxyresveratrol-loaded NLC had a smaller and more uniform nanoparticle size, significantly higher efficiency for oxyresveratrol entrapment (89%), and better stability than

---

**Fig. 2.** A) Number of publications related to formulated BPCs per year. B) Publication proportions of formulated BPCs from 1985 to 2019. The data were obtained from PubMed using the following keywords: natural compound, natural product, liposome, nanoemulsion, solid lipid nanoparticle, phytosome, nanoparticle, nanostructured lipid carrier, formulation.
SLN by a 12-month storage period. In in vivo absorption studies, oxyresveratrol-loaded NLC increased the relative bioavailability of oxyresveratrol by 177% compared with unformulated oxyresveratrol.

2.3. Phytosomes

A considerable proportion of bioactive phytocompounds are polar and water-soluble molecules, and water-soluble phytocompounds are poorly absorbed in phospholipid structures because of their intrinsic limitation of relatively large molecular size, which interferes with absorption by passive diffusion and low lipid solubility, limiting their ability to pass across the lipid-rich biological membrane, resulting in poor encapsulation efficacy and bioavailability. To solve these problems, researchers have developed phytosomes to enhance the bioavailability of water-soluble BPCs [71,72].

Structurally, phytosomes use phospholipid molecules containing phosphatidylcholine to form complexes with BPCs. Conventional liposomes are obtained by simply mixing water-soluble BPCs with phospholipids with no chemical bond formation, while phytosomes are assembled via phyto-phospholipid complexes-forming hydrogen bonds by reacting a stoichiometric amount of the phospholipid polar heads with the functionalities of the polar BPCs in a suitable solvent. Therefore, unlike liposomes where BPCs are distributed in the central space or the layers of the membrane, phytosomes have an essential part where BPCs are stabled through the hydrogen bond to the polar head of the phospholipids. Given the stable incorporation of BPCs in phytosomes,
Table 3
Formulations and characteristics of bioactive phytocompound-based nanomedicine.

| Type                      | Natural compound | Formulation method                  | L.C (%) /L.E (%) | Size (nm) | Features                                                                 | Ref       |
|---------------------------|------------------|-------------------------------------|------------------|-----------|---------------------------------------------------------------------------|-----------|
| Liposomes                 | ART              | Thin-film hydration                 | -/90 76 ± 10     |           | pH-responsive ART dimer in lipid formulation                              | [96]      |
|                           | CCM              | -/50 100 ± 23                       |                  |           | Entrapment of CCM by CD complexation                                      | [97]      |
|                           | CCE E            | -/76 140-350                        |                  |           | Rapid CCM release under HFMF exposure                                     | [98, 99]  |
|                           | EB               | -/85 500-734                        |                  |           | Changes of lipid membrane structure by CCE E encapsulation               | [100]     |
|                           | MA               | -/40 293                            |                  |           | Optimization of EB loaded formulations depends on composition parameters | [57]      |
|                           | Melanin          | 9/89 300                            |                  |           | Controlled in vitro quercetin release by adjusting cremophor RH40         | [102]     |
|                           | Quercetin        | -/90 182 ± 1                        |                  |           | Photothermal effect under 808 nm laser                                   | [103]     |
|                           | RVT              | -/78 122-140                        |                  |           | Various factor-based RVT loaded lipidal characteristics: pH, ion strength, and temperature | [104]   |
|                           | SA               | -/96 21 ± 1                         |                  |           | Increase in the stability of SA via steric hindrance by TPGS-based lipidosomal bilayer | [105]   |
|                           | TMP              | -/86 168 ± 14                       |                  |           | Penetration of TMP in blood-brain barrier models in vitro and ex vivo     | [106]   |
|                           | Vitamin C        | -/48 67 ± 6                         |                  |           | Change of vitamin C’s stability and skin permeation by the content of pectin in lipidal structure. | [107]   |
| Nano Emulsions            | BCL              | Emulsification and high-pressure homogenization | -/99 90         |           | Hemp oil-based NE with reduced surfactants for oral delivery of BCL     | [91]      |
|                           | CCM              | Emulsification                      | -/91 103 ± 11    |           | Characteristics of formulation depend on vegetable oil for dissolution of CCM: encapsulation efficiency, size, and bioavailability | [108]   |
|                           | Imperatorin      | Ionic gelation                      | -/90 168 ± 2    |           | Optimization of lipid microsphere formulation for response surfaceentral composite design | [109]   |
|                           | Lycopene         | High-pressure homogenization        | -/51 184 ± 20   |           | In vitro antioxidant activity and bioaccessibility of differently-sized NEs | [110]  |
|                           | β-sitosterol     | Emulsification                      | -/72 ± 87 163-258 |           | Formation of lipid formulations by combination of natural oils and lipids | [90]      |
|                           | TQ               | Ionic gelation                      | -/99 95 ± 7     |           | TQ-loaded mucoadhesive NE for intranasal administration                  | [92]      |
| Self-assembled NPs or other NPs | CCM              | Ionic gelation                    | -/50 70-90      |           | LDH-NP based photodynamic effects under 465 nm laser                    | [111-113]|
|                           |                 | Opposite charge ion precipitation   | -/8/- 63        |           | In vitro pH-responsive CCM release from MSN                              | [80]      |
|                           |                 | Physical encapsulation             | 7/85 37 ± 6     |           | Photoprotective effect of PLGA-CCM-NP under UV irradiation              | [114]   |
|                           |                 |                                       | -/100           |           | MRI-guided photochemotherapy                                             | [115]   |
|                           |                 | EGCG                               | -/- 109 ± 30    |           | Conjugated EGCG to end-HA (98% degree of substitution)                  | [84]      |
|                           |                 | Gossypol                           | 91/97 43 ± 2    |           | Loading of ciplatin to EGCG core in HA-EGCG micelle                     | [116]   |
|                           |                 | Lycopene                           | 9/89 152 ± 32   |           | In vitro pH-dependent DOX release from gosypol-DPA NP                   | [85]      |
|                           |                 |                                    |                 |           | Structural antioxidant property by EGCG for protection of lycopene      |           |
|                           | PTX              | Solvent evaporation                 | -/42 43         |           | In vitro acid-triggered PTX release from self-assembled peptide         | [81]      |
|                           | QCT              | Nanoprecipitation                  | 29/81 100       |           | Co-delivery of QCT and DOX using MSN                                    | [117]     |
|                           | Vitamin E        | Physical interaction               | -/99 130-350    |           | Polysaccharide-based NP film formulation including vitamin E for topical administration | [82] |
| NLCs                      | Bixin            | High-pressure homogenization       | 17/9 136-353    |           | Increase in uptake and localization at liver                              | [118]     |
|                           |                 |                                       | >99             |           |                                                                           |
| Niosomes                  | ZER              | High-shear homogenization           | -/99 52         |           | Stable at 4, 25, and 40 for at least one month.                           | [119]     |
|                           | Boswellic acid   | Co-acervation phase separation      | -/98 708        |           | Topical proniosomal gel with enhanced bioavailability                    | [120]     |
|                           | CCM              |                                       | -/59 71 ± 1     |           | Fast production of CCM-loaded niosomes with small size in a single step  | [121]     |
|                           | α-M              | Thin-film hydration                 | -/99 180 ± 30   |           | Relation between skin permeation and concentration of mangostin by non-ionic surfactant | [122] |
|                           | OXY              | Microfluidic mixing                | >5/- 96-108     |           | Optimization formulated using NLC and SNP for improved oral bioavailability | [70]      |
| Phytosomes                | Apigenin         | Sequential co-loading prior to thin film evaporation | 31/99 361-400 |           | Optimal entrainment method for multiple phenolic flavonoids in a single entity | [83]|
|                           | CCM              |                                         | 34/99 875       |           | Three kinds of surfactant effect: stability, antioxidant capacity, and loading efficiency, physicochemical properties of NEs | [123] |
|                           | Kaempferol       |                                         | 31/98 376 ± 34  |           | Optimal entrainment method for multiple phenolic flavonoids in a single entity | [83]|
|                           | QCT              | High-shear homogenization           | -/49 58 ± 13    |           | Ionotropic gelation of alginate by cross-linking with calcium ions       | [124]     |
|                           | CCM              |                                       |                 |           |                                                                           |           |

ART: artemisinin; BCL: baicalein; CuC E: cucurbitacin E; CCM: curcumin; DOX: doxorubicin; DPA: dopamine; EB: embelin; EGCG: epigallocate-chin-3-O-gallate; LDH: layered double hydroxide; LF: lactoferrin; MA: madecassoside; MSN: mesoporous silica nanoparticles; NE: nanoemulsion; NF: nanoformulation; NLG: nanostructured lipid carriers; NP: nanoparticle; OEGCG: oligomerized (—)–epigallocatechin-3-O-gallate; OXY: oxyresveratrol; PLGA: poly(lactic-co-glycolic) acid; PTX: paclitaxel; PPI: pharmacobind; QCT: quercetin; RVT: resveratrol; SLN: solid lipid nanoparticles; SFN: sulforaphane; SA: syringic acid; TMP: tetramethylpyrazine; TQ: thymoquinone; ZER: zerumbone; α-M: α-mangostin.
Table 4
Therapeutic application of bioactive phytocompound-based nanomedicine for disease treatment.

| Category          | Type               | Therapeutic agent | Target                     | Therapeutic outcome                                                                 | Refs |
|-------------------|--------------------|-------------------|----------------------------|--------------------------------------------------------------------------------------|------|
| Anticancer        | Liposome           | CCM               | Breast cancer              | Apoptotic cell death in MCF-7 human breast cancer cells                                | [97] |
|                   |                    | Breast/lung cancer|                            | Cytotoxic effects on MCF-7 and A549 cells                                             | [98,99] |
|                   |                    | Celastrin         | Prostate cancer            | Anticancer effects on vertebral cancer of prostate cells                              | [187] |
|                   |                    | GEVPG             | Breast/lung cancer         | In vitro antitumor effect on MDA-MB-231, MCF-7, SKBR-3, and A549 cancer cells          | [188] |
|                   |                    | GCK               | Lung cancer                | Hypersensitizing effect on A549 cancer cells                                          | [189] |
|                   |                    | QCT               | Breast cancer              | Anticancer effect of liposomal quercetin on MCF-7 cancer cells                         | [190] |
|                   |                    | SFN               | Breast cancer              | Combination therapy with doxorubicin for MDA-MB-231 cancer cells                       | [191] |
|                   |                    | WG                | Liver cancer               | Increase in anticancer effect on HepG2 cancer cells by targetable GA-modified liposomes | [192] |
|                   |                    |                   |                            | (1.5 times of free WG)                                                                |      |
|                   |                    |                   |                            | Increase in in vitro cytotoxicity in U87-MG cancer cells (2.5 times of free PTX)      | [193] |
|                   |                    |                   |                            | Increase in anticancer activity in SCC4 and A431 cancer cells (5-6 times of free toctenrol) | [194] |
|                   |                    |                   |                            | Increase in in vitro cytotoxicity of CCM (1.8 times of free CCM)                      | [195] |
|                   |                    |                   |                            | Increase in in vitro cytotoxicity of SA (9.8 times of free SA)                        | [196] |
|                   |                    |                   |                            | Anticancer activity against SH-SY5Y cancer cells                                      | [197] |
|                   |                    |                   |                            | Cytotoxicity to DU145 cancer cells                                                    | [198] |
|                   |                    |                   |                            | High hemocompatibility (<0.1% hemolysis)                                              | [199] |
|                   |                    |                   | Breast cancer              | Increase in CCM’s stability (48 times of free CCM)                                    | [200] |
|                   |                    |                   |                            | Increase in anticancer activity to MCF-7 cancer cells (1.8 times of free CCM)         | [201] |
|                   |                    | CHE               | Liver cancer               | In vitro inhibitive effect on HepG2 cancer cells                                      | [202] |
|                   |                    | DL                | Cervical cancer            | Antiproliferative activity against human cervical cancer Hela cells.                  | [203] |
|                   |                    | Gossypol         | Prostate cancer            | High maximum tolerated dose (>60 mg/kg)                                              | [204] |
|                   |                    | Hesperetin       | Colon cancer               | Lower IC value (7 times of free hesperetin)                                           | [205] |
|                   |                    | QCT               | Gastric cancer             | Induction of apoptosis in HCT15 cancer cells                                           | [206] |
|                   |                    |                  | Gastric cancer             | Anticancer effect on SGC7901/ADR cells                                               | [207] |
|                   |                    |                  | Gastric/lung cancer        | Decrease in oxidative stress (~5.0 times of free BBR)                                 | [208] |
|                   |                    |                  |                            | Induction of apoptosis in HSTR-231 cancer cells                                       | [209] |
|                   |                    |                  |                            | Antitumor effect on A2780 cancer cells                                               | [210] |
|                   |                    |                  |                            | Cytotoxicity towards SK-BR-3 cancer cells (3 times of free PTX)                       | [211] |
|                   |                    |                  |                            | Prostate cancer                                                                       | [212] |
|                   |                    |                  |                            | Anti-leukemic effect on Jurkat cells                                                 | [213] |
|                   |                    | NLC               | TQ                         | Anti-metastasis effect on the lungs                                                  | [214] |
|                   |                    | ZER               | Leukemia                   | Anti-leukemic effect on Jurkat cells                                                 | [215] |
|                   |                    | Niosome          | LAW                        | Increase in in vitro cytotoxicity towards MCF-7 cancer cells (1.3 times of free LAW) | [216] |
| Anti-inflammation  | Phytosome          | RVT               | Prostate cancer            | High hemocompatibility (<0.1% hemolysis)                                              | [217] |
|                   | Liposome           | SA                | Heparic                    | Increase in oral bioavailability and liver accumulation of SA (9.8 times of free SA) | [218] |
|                   |                    | BBR               | Diabetes                   | Decrease in ROS generation (~3.5 times of free BBR)                                   | [219] |
|                   |                    | EB                | Ulcerative colitis         | Anti-inflammatory activity by an increased accumulation in colon tissue               | [220] |
|                   |                    | EGGG              | Psoriasis                  | Decrease in psoriasiform pathological markers (p < 0.01)                              | [221] |
|                   |                    | SCU               | Retinopathy                | Allleviation of structural disorder of intraretinal neovessels in the retina induced by diabetes | [222] |
|                   |                    | NLC               | TQ                         | Gastric ulcer                                                                       | [223] |
|                   |                    | CCM               | Odema                      | Decrease in cytotoxic effect to normal human hepatic cell (1.9 times of free TQ)     | [224] |
|                   |                    | EB                | Diabetes                   | Increase in hypoglycemic activity and antioxidant efficacy (1.7 times of free EB)     | [225] |
|                   |                    | Sinigrin          | Skin wound                 | Increased wound healing (1.4 times of free Sinigrin)                                 | [226] |
|                   |                    | QCT               | Menopause                  | Ameliorating effect in inflammation, oxidative stress, bone, lipid, blood glucose, and weight gain parameters | [227] |
|                   |                    | SLN               | Bixingin                   | Allleviation in histopathological feature (moderate to absence or mild appearance) | [228] |
|                   |                    | SG                | Gastric ulcer              | Increase in protective effect on ethanol-induced gastric ulcers in mice (1.8 times of free SG) | [229] |
| Anti-bacterial     | Liposome           | Allicin           | Food preservation          | Antimicrobial effect against Listeria spp.                                            | [230] |
|                   |                    | Gingerol         | Respiratory infection      | Increase in antioxidant and anti-inflammatory activity for oral adsorption (20 times of free Gingerol) | [231] |

(continued on next page)
pfyotosomes can significantly improve the permeability of BPCs to the outer membrane of target cells as well as provide robust stability over conventional liposomes [73]. Therefore, phytosomes are more readily absorbed into the body and achieve higher bioavailability than free BPCs.

Based on these superior properties, NPs using phytosomes have been applied to various kinds of BPCs, such as ginkgo, milk thistle, green tea, curcumin, and silybinin [74]. Phytosomes anchoring BPCs can boost absorption through oral administration, increasing the bioavailability and reducing the required dose. In addition, phytosomes can also increase the percutaneous absorption of BPCs, improving skin penetration [75].

### 2.4. Self-assembled nanoparticles or other nanoparticles

In recent decades, there has been growing research interest in nanoparticle-based drug formulations for biomedical applications [76, 77]. Exemplary nanoparticle formulations are summarized in Table 3. Nanoparticle-based drug delivery nanocarriers can be constructed based on polymers, proteins, lipids, carbohydrates, and inorganic materials. Notably, the main materials of nanoparticles determine their physicochemical and biological properties. For instance, carbohydrates are mostly hydrophilic, many inorganic materials are hard and bio-inert, and the characteristics of polymers can be tailored by controlling the types of repeating units and their molecular weight. The types of nanoparticles include i) self-assembled nanoparticles (e.g., polymeric solid nanoparticles, self-assembled micelles or aggregates based on polymers, lipids, proteins, or carbohydrates, and polymersomes) and ii) inorganic nanoparticles (e.g., gold, iron oxide, silver, and silica-based nanoparticles). Depending on nanoparticle type, drugs can be encapsulated in nanoparticles or conjugated with their surface.

Given the low bioavailability of many BPCs, prolonged in vivo circulation is critical for improving the delivery efficiency of BPCs into target tissues and increasing their therapeutic potential. Nanoparticulate formulations increase drug solubility, protect BPCs from premature chemical or enzymatic degradation in the body, improve the bioavailability of BPCs compared with the corresponding crude drugs, and reduce medicinal doses [78, 79]. Many BPCs, such as quercetin, paclitaxel, curcumin, and vitamin E, have been encapsulated within nanoparticulate formulations to enhance their solubility, bioavailability, pharmacokinetic, and pharmacodynamic properties by improving biodistribution and facilitating entry into the target tissue [80–83]. However, BPCs themselves have also been exploited as a hydrophobic core to form self-assembled nanoparticles. Recent studies have demonstrated that chemical modification of the hydrophobic BPC epigallocatechin gallate with biopolymers, such as chitosan and hyaluronic acid, allows the nanoparticle formulation to protect BPCs from degradation and deliver them to the target tissues with high efficiency [84, 85].

### 2.5. Nanoemulsions

Nanoemulsions are heterogeneous systems in which one liquid with nano-sized droplets forms a dispersed phase, while another surrounding liquid forms a continuous phase [86]. Generally, nanoemulsions have droplet sizes between 20 and 500 nm, and their types are determined by the class of the dispersed and continuous phases; for example, single emulsions include oil-in-water (O/W) and water-in-oil (W/O), and double emulsions include W/O/W and O/W/O. In terms of fabrication, nanoemulsions can be relatively easily prepared with bio-compatible and biodegradable ingredients, including FDA-approved oils. Because these nanoemulsions are non-equilibrium and kinetically stable, surfactants or emulsifiers can be used to impart colloidal stability in their formation. Nanoemulsions have evolved as attractive carriers for the delivery of drugs, including BPCs, nucleic acids, and imaging agents, owing to their favorable features, such as ease of production, enhanced loading capacities for poorly water-soluble drugs, in vivo long-term stability, protection and controlled release of cargo, and ability to accumulate in pathological areas with defective vasculature [87–89].

Some studies have demonstrated that BPCs, such as baicalein, β-sitosterol, and thymoquinone, can be stabilized by forming nanoemulsions and sustainedly releasing them from the nanoemulsions [90–92]. For targeted drug delivery, intelligent nanoemulsion systems with unique structures have been used for targeted drug delivery [93]. For example, perfluorooctyl bromide and camptothecin were co-loaded into poly(lactic-co-glycolic acid) (PLGA) nanocapsules with ultrathin silicon coating [94]. PLGA dispersed in chloroform solution containing perfluorooctyl bromide, camptothecin, and cetyltrimethylammonium bromide to form an oil-water two-phase emulsion and followed by ultrasonic emulsification and solvent evaporation. The nanoemulsions exhibited a very high loading capacity of up to 19% for the camptothecin. Owing to the structural advantage of ultrathin silica, the release rate of camptothecin is very low under physiological conditions, while high-intensity focused ultrasound triggering can induce an accelerated release of camptothecin. Such distinct drug release provides a synergistic effect of high-intensity focused ultrasound-enhanced ablation and chemotherapy for tumor tissue, inhibiting tumor recurrence.

Furthermore, a transformer-like nanoemulsion was fabricated by self-emulsification in the intestinal lumen after oral administration of an enteric-coated gelatin capsule containing an acid initiator, forming an agent, surfactant, and curcumin [95]. The transformer-like nanoemulsions with diameters of 300–900 nm and 80–90% curcumin encapsulation efficiency could be transcysclogged into intestinal M cells, resulting in high accumulation in pancreatic tissue via the intestinal lymphatic system. In this regard, the nanoemulsion strategy provides increased absorption of lipophilic BPCs within the body, indicating targeted delivery and prolonged action for BPCs, thereby improving their bioavailability.
3. Therapeutic applications of BPC-NF

Over time, plants have evolved to biosynthesize various BPCs to survive and protect themselves against environmental challenges. These BPCs have shown potential as therapeutic agents against cancer, inflammatory diseases, microbial infection, oxidative stress, and neurological disorders. However, their biomedical applications have been significantly hampered by several obstacles, including their poor solubility, low stability, low bioavailability, rapid clearance from the body, and off-target toxicity. For this reason, various formulation strategies have been developed to increase their solubility and stability and facilitate controlled release at the target site, thereby improving the bioavailability of BPCs in a physiological environment. This section reviews recent BPC-NFs for anticancer, anti-inflammatory, antibacterial, antioxidant, and anti-neurodegenerative applications (Table 4).

3.1. Anticancer

BPCs have been explored as a major source of cancer therapeutics and offered new chemical entities with selective activity against cancer-related molecular targets for anticancer drug discovery [125–127]. The anticancer effects of BPCs include many different mechanisms of action, such as the inhibition of tumor cell growth, induction of apoptosis, DNA damage, and inhibition of topoisomerases I and II. Moreover, to overcome the inherent limitations of BPCs for clinical use, researchers have developed BPC-NFs, which can selectively deliver BPCs to tumor tissue and improve the bioavailability and therapeutic outcome.

Epigallocatechin-3-O-gallate, a major constituent of green tea, is one of the most potent and promising chemopreventive agents [128, 129]. Recently, epigallocatechin-3-O-gallate was used as a carrier for biological molecules and as an anticancer drug to achieve synergistic anticancer effects [130]. The sequential self-assembly of the

Fig. 4. A) Preparation procedure for lipid calcium phosphate-quercetin phosphate (LCP-QP). B) Transmission electron microscopy image of LCP-QP final particles. C) Tumor volume changes for LCP-QP, cisplatin nanoparticles (LPC), and LCP-QP + LPC on a stroma-rich UMUC3 bladder cancer xenograft model after five IV injections (blue arrows, four mice per group. D), E), F) Effects of different treatments on the inhibition of fibroblast growth and Masson’s trichrome stain for collagen and quantification results expressed as a percentage of total cell number. **p < 0.01, *p < 0.05, n = 5. Adapted with permission [133]. Copyright 2017, American Chemical Society.

Fig. 5. A) Principle scheme of the synthesis of quercetin-modified Zr-MOF nanoparticle (Zr-MOF-QU) nanocarriers and schematic illustration of the nanoparticle-based therapeutic principle for dual sensitization radiation therapy of tumors and the mechanism of relieving hypoxia in the tumor microenvironment B) Tumor volumes of different groups in A549 tumor-bearing mice. C) Representative results of an A549 MTT assay in different groups, including a control, RT, QU + RT, Zr-MOF + RT, and Zr-MOF-QU + RT. The results from 24 to 48 h show a statistically significant difference. The p values were calculated by Student’s t-test. *p < 0.05, **p < 0.01, ***p < 0.001. D), E) Intensity expression levels of HIF-1a and CA IX in control, RT, QU + RT, Zr-MOF + RT, and Zr-MOF-QU + RT groups. *p < 0.05, **p < 0.01, ***p < 0.001. Adapted with permission [136]. Copyright 2019, American Chemical Society.
epigallocatechin-3-O-gallate derivative with anticancer proteins such as Herceptin and interferon α-2a led to the formation of micellar nanocomplexes, which exhibited robust stability in serum for 15 days without a change in size. In vitro experiments indicated that Herceptin-loaded micellar nanocomplexes showed an excellent inhibitory effect on HER2-overexpressing human breast cancer cells but an insignificant suppression effect on normal cells. Interferon α-2a-loaded micellar nanocomplexes also displayed a superior inhibitory effect on human liver cancer cells than free Interferon α-2a. These enhanced anticancer effects were supported by in vivo results, which demonstrated that both Herceptin- and Interferon α-2a-loaded micellar nanocomplexes exhibit longer blood half-life, higher tumor selectivity, and better growth reduction compared with free Herceptin and free Interferon α-2a.

In addition to using BPCs as carrier molecules for anticancer therapies, the phosphorylation approach has been used to improve the solubility of natural compound-based prodrugs [131,132]. For example, researchers have developed a quercetin prodrug via phosphorylation of the hydroxyl groups of quercetin (Fig. 4) [133].

As a result, quercetin phosphate increased its solubility in aqueous conditions. Moreover, it facilitated its precipitation with calcium to be encapsulated into lipid calcium phosphate nanoparticles with a high loading efficiency (26.6% w/w). The nanoparticles protected the quercetin phosphate from degradation and improved its tumor accumulation via the enhanced permeability and retention effects. In particular, quercetin phosphate released from the nanoparticles was replaced with the parent quercetin in response to abundant phosphatases in the tumor tissue. Furthermore, when the nanoparticles were intravenously co-injected with cisplatin nanoparticles, they induced synergistic anti-tumor effects, decreasing the active fibroblasts and collagen content in the tumor microenvironment. These results suggest that BPC-NFs are a safe and effective way to modulate the tumor microenvironment and assist in traditional chemotherapy for cancer treatment.

Quercetin has also been employed for tumor radiotherapy because of its ability to enhance the sensitivity to radiotherapy and kill cancer cells [134,135]. For instance, researchers prepared quercetin-loaded Zr-metal-organic framework nanoparticles to improve the irradiation energy absorption and downregulate hypoxic tumor conditions (Fig. 5) [136]. The nanoparticle was fabricated using Zr-metal-organic framework as a carbonic anhydrase IX inhibitor and quercetin as a radiosensitizer for dual sensitization of radiotherapy in hypoxic tumors. Owing to its large surface area and porous structure, the nanoparticles contained a large quantity of quercetin (20.7%) inside the nanostructure. After intravenous administration to A549 tumor-bearing mice, the nanoparticles effectively suppressed carbonic anhydrase IX expression by 1,4-benzene dicarboxylic acid generated from the nanoparticles and boosted the sensitivity of tumor tissues by quercetin, showing no significant side effects during radiation therapy. These examples suggest that BPC-NFs are potential anticancer therapeutics for treating various cancers with high efficiency and low off-target toxicity.

3.2. Antiinflammation

BPCs have long been explored as a folk remedy for inflammatory diseases, as seen in the first description of the four classic signs of inflammation and the use of BPCs to relieve them [137]. With our increasing understanding of inflammation, many BPCs with anti-inflammatory activity have been investigated to treat many severe disorders, including cancer, diabetes, gastrointestinal disorders, and liver disorders and eventually enter the commercial market. For example, plants containing salicylate have led to the production of major anti-inflammatory drugs, such as aspirin [138].

NFs have shown great promise for treating inflammatory diseases by optimizing the properties such as size, surface charge, or decorating their surface with coating group (PEG), specific antibodies, or other affinity ligands (small molecules, peptides, aptamers) [139]. In addition, well-designed NFs can target effector cells, such as antigen-presenting cells, membrane receptors on inflammatory cells such as Toll-like receptors, and macrophages through phagocytosis, and regulate the expression of pro- and anti-inflammatory molecules [140,141].

Celastrol, a pentacyclic triterpene extracted from Thunder God Vine, is a potent immunosuppressive, anti-inflammatory, and anticancer agent [142]. In a recent study, researchers fabricated celastrol-loaded albumin nanoparticles to treat mesangioproliferative glomerulonephritis using albumin with excellent biocompatibility and high binding affinity with celastrol (Fig. 6) [143]. Ex vivo distribution data demonstrated that FITC-labeled nanoparticle was extensively distributed...
throughout the kidneys and displayed the highest renal accumulation compared to control groups. These results were supported by the enhanced therapeutic efficacy after treatment with nanoparticles in the rat anti-Thy1.1 nephritis model. In addition, the nanoparticles altered the biodistribution behavior of celastrol with reduced drug accumulation in the heart, brain, and liver, minimizing celastrol-related off-target toxicity.

Berberine, an isoquinoline quaternary alkaloid extracted from berberis spp., has been associated with anti-inflammatory effects\[144\] and cardioprotective properties. In contrast, its utilization has been hampered because of its low solubility and short half-life in the body after administration. To address these limitations, researchers have developed a long-circulating, berberine-encapsulated liposome that can reduce adverse cardiac remodeling after myocardial infarction and protect heart function in a myocardial infarction mouse model (Fig. 7)\[145\]. When berberine-loaded liposomes were intravenously administered, they significantly preserved the cardiac ejection fraction at day 28 compared to a control group and free berberine injection. NF strategies using liposomal encapsulation significantly enhanced berberine’s water-solubility and therapeutic efficacy to protect cardiac function in an animal model of myocardial infarction.

In one study, researchers demonstrated H$_2$O$_2$-responsive copolyoxalate-loaded vanillyl alcohol (PVAX) nanoparticles as curcumin carriers to treat ischemic diseases, such as peripheral artery disease\[146\]. Curcumin, a highly potent antioxidant, anti-inflammatory, and angiogenic BPC, was encapsulated in PVAX nanoparticles by a single emulsion method. The nanoparticles had mean diameters of 360 nm (PDI: 0.152) and contained 10 wt% curcumin in the nanostructure. When the nanoparticles were treated with RAW 264.7 cells in the presence of H$_2$O$_2$ stimulation, the expression levels of TNF-$\alpha$ and IL-1$\beta$ were significantly downregulated, indicating their anti-inflammatory activity. Interestingly, the nanoparticles generate CO$_2$ bubbles in response to H$_2$O$_2$ and release both vanillyl alcohol and curcumin; thus, the nanoparticles could be used to increase ultrasound contrast in the ischemic site associated with a high level of H$_2$O$_2$. The nanoparticles also suppressed the expression of pro-inflammatory cytokines in a mouse model of ischemic injury. Of particular note, this study demonstrated that BPC-NFs hold potential as theranostic agents for imaging and treating ischemic diseases.

Rosmarinic acid has also been considered as an anti-inflammatory, anticancer, and antibacterial BPC. Rosmarinic acid-based nanoparticles were developed as anti-inflammatory nanomedicine for the treatment of inflammatory bowel disease in a dextran sulfate sodium (DSS)-induced acute colitis mouse model\[147\]. The nanoparticle with a mean diameter of 64 $\pm$ 4 nm showed high colloidal stability for up to 2 weeks in a physiological environment and effectively protected CHO–K1 cells from H$_2$O$_2$-induced damage by effectively scavenging H$_2$O$_2$. Moreover, the nanoparticles exhibited significantly prolonged circulation and preferential accumulation in inflamed colon tissue. In addition to this, the nanoparticles showed improved therapeutic efficacy in the colitis model by encapsulating dexamethasone in the nanostructure, implying synergistic effects with a conventional drug. These results suggest that BPC-based NFs warrant further consideration as potential therapeutic nanomedicines for treating various inflammatory diseases, including inflammatory bowel disease.
3.3. Antimicrobial

BPCs have been recognized as a valuable resource for the development of antimicrobial agents. Moreover, the rapid emergence of resistant bacterial strains has forced the re-evaluation of BPCs as a route to identify novel chemical skeletons with antibiotic activity. Nevertheless, the contributions of BPCs in the development of new antibiotics have been mostly through semisynthetic tailoring of BPCs discovered in the middle of the 20th century.

Fortunately, advances in nanotechnology and pharmaceutics have led to the development of NF strategies to improve the antibiotic effects of BPCs and overcome resistance issues [148]. BPC-NFs have been utilized to combat multidrug-resistant organisms by enhancing their antibiotic effects and inhibiting biofilm formation, as well as by overcoming common resistance mechanisms, such as enzyme inactivation, decreased cell permeability, modification of target sites/enzymes, and increased efflux via overexpression of efflux pump [149,150].

Quercetin, a highly abundant flavonoid found in fruits and vegetables, has been used to treat several diseases. To achieve synergistic antibacterial effects, researchers have developed silver nanoparticle-decorated quercetin nanoparticles [151]. The nanoparticles have displayed enhanced antibacterial activities and cellular uptake against drug-resistant E. coli and S. aureus compared to quercetin or silver nanoparticles alone. Furthermore, in vivo studies using infected mice demonstrated that bacteria gradually decreased over time and were at almost similar levels to the control group on day 5 after administration of the nanoparticles. These enhanced antibacterial activities of the nanoparticles could be attributed to the morphological changes of E. coli and S. aureus, leading to bacterial death by direct cell membrane damage by silver nanoparticles and quercetin dissociated from the nanoparticles trapped in bacteria.

Reactive oxygen species, such as hydroxyl radicals (•OH), have been used to reduce bacterial resistance [152,153]. Ascorbic acid, a pro-oxidant and potent antioxidant, acts as a prodrug of H₂O₂ to treat drug-resistant infections, improving antibacterial efficiency in the presence of peroxidase. In one study, researchers prepared a targeted “on-demand” prodrug ascorbic acid delivery system, consisting of hyaluronic acid-capped graphene-mesoporous silica nanoshells as the carrier, ferromagnetic nanoparticles as a peroxidase-like catalyst, and ascorbic acid as a prodrug for the treatment of bacterial infection. Ascorbic acid treatment displayed minor antibacterial activity due to the slow decomposition of the generated H₂O₂. In contrast, the antibacterial ability of the nanocarriers was notably improved at a much lower concentration due to their high catalytic activity. The nanocarriers exhibited excellent antibacterial activity against E. coli and S. aureus, given the high targetability of HA, •OH generated from ferromagnetic nanoparticles and the photothermal effect from graphene mesoporous silica nanoshells. These studies substantiated that targeted “on-demand” BPC-NFs could help treat bacterial infections and overcome bacterial resistance.

3.4. Antioxidation

Oxidative stress is the process of cell damages caused by reactive oxygen or nitrogen species (RONs), such as •OH, H₂O₂, nitric oxide, peroxide, peroxynitrite, singlet oxygen (¹O₂), and superoxides [154]. Generally, plants contain many biological compounds, such as ascorbic acid and glutathione, an antioxidant that blocks oxidative stress [155]. Based on these innate defense mechanisms, many natural compounds have been used to treat oxidative stress-associated diseases or to reduce the side effects of drugs that generate RONS [156].

Recently, NPs have been employed as antioxidant delivery vesicles or antioxidants to enhance antioxidant activity under oxidative stress conditions and provide targeted delivery of certain antioxidants with...
Hepatitis C is a viral infection that causes oxidative stress and leads to liver fibrosis, liver cirrhosis, and hepatocellular carcinoma [157, 158]. As hepatitis C treatment, researchers utilized silibinin, a flavonolignan isolated from Silybum, which is known to be an excellent hepatoprotective antioxidant [159, 160]. A recent study demonstrated the encapsulation of silibinin into hydrophilic polyvinylpyrrolidone via a simple nano-emulsification technique to improve the solubility and bioavailability of silibinin (Fig. 8) [161].

Silibinin-loaded polyvinylpyrrolidone nanoparticles increased the solubility of silibinin by over 75% while maintaining anti-hepatitis C virus and antioxidant activities, resulting in remarkable suppression of hepatitis C virus-induced oxidative stress in primary human hepatocytes. After oral administration of silibinin-loaded nanoparticles in an animal model, the serum level and biodistribution to the liver were significantly enhanced compared with non-modified free silibinin, indicating the enhanced bioavailability of the nanoparticles.

In addition to hepatitis C, elevated RONS levels have been implicated in developing RONS-associated diseases, such as brain ischemia. During brain ischemia, the generated RONS can dramatically aggravate an oxidative injury and lead to RONS-induced inflammation in the brain tissue [162, 163]. Melanin, a heterogeneous biological polymer, has attracted increasing attention in photoacoustic imaging, magnetic resonance imaging, and photothermal therapy [164-167]. Interestingly, some reports have shown the antioxidant effects of melanin as a radical scavenger by broad antioxidative activities against multiple toxic RONS, including $\cdot O_2$, $\cdot O_2^-$, $\cdot OH$, ONOO$^-$, and $\cdot NO$. In addition, the nanoparticles exhibited neuroprotective and anti-inflammatory effects in Neuro 2A and activated macrophage cells. In particular, in a rat model of ischemic stroke, pre-treatment of the nanoparticle decreased the infarct area by a factor of two compared to the control group and suppressed the generation of $O_2^*$ in the brain tissue. Altogether, these findings demonstrate that polyethylene glycol-conjugated melanin nanoparticles can be useful as antioxidants and neuroprotective agents for treating RONS-associated diseases.

Catechin, a highly bioactive polyphenol, has been widely studied due to its excellent RONS scavenging activity, inhibition of xanthine oxidase and many proteinases associated with ROS generation [172, 173]. However, the practical application of catechin has been hindered by its poor bioavailability, pro-oxidant activity, and easy degradation by basic solutions or light [172]. To address these issues, researchers have developed polymerized catechin-capped gold nanoparticles via self-polymerization and self-assembly to treat dry eye disease, a ROS-induced inflammatory disease [174]. In the nanostructure, polymerized catechin acts as a drug carrier to deliver anti-inflammatory drugs and as a drug itself to attenuate ROS-induced damage. In vitro results demonstrated that polymerized catechin-capped gold nanoparticles acted as an antioxidant by suppressing ROS and the COX-2 enzyme and served as a drug carrier of amfenac to have a synergistic effect on dry eye conditions. When the nanoparticles were topically administered, they exhibited superior recovery efficacy in a rabbit DED model through long retention time in the blood and dual suppression effects on ROS and inflammation compared to the commercially available cyclosporine A. From these results, the nanoparticles have shown significant potential as dual-functional BPC-NFs for the simultaneous treatment of anti-inflammatory and anti-oxidative diseases. These studies indicate that BPC-based NFs can be used as potent antibiotic scavenger by broad antioxidative activities against multiple toxic RONS, including $O_2^-$, $H_2O_2$, $\cdot OH$, ONOO$^-$, and $\cdot NO$. In addition, the nanoparticles exhibited neuroprotective and anti-inflammatory effects in Neuro 2A and activated macrophage cells. In particular, in a rat model of ischemic stroke, pre-treatment of the nanoparticle decreased the infarct area by a factor of two compared to the control group and suppressed the generation of $O_2^*$ in the brain tissue. Altogether, these findings demonstrate that polyethylene glycol-conjugated melanin nanoparticles can be useful as antioxidants and neuroprotective agents for treating RONS-associated diseases.
3.5. Anti-neurodegeneration

Neurodegradative diseases such as Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease are incurable and debilitating conditions. Although various therapeutic strategies have been introduced to modulate neurodegenerative diseases, current therapies are limited because of the poor permeability of drugs through the blood-brain barrier. Therefore, there is an urgent need to develop effective therapeutic strategies to deliver drugs to the central nervous system [175, 176]. Blood-brain barrier penetration strategies, such as adsorptive and receptor/transporter-mediated transcytosis and targeting specific domains within brain tissues, can enhance the delivery efficiency of NFs to brain lesions. With the development of brain-targeted drug delivery systems, NFs can interact with target cells and tissues in the brain to induce the preferred physiological response while lowering harmful side effects.

Induction of neurogenesis, which is a process of generating new neurons, can be a potential target for treating neurodegenerative diseases [177]. Curcumin, a natural polyphenol compound derived from the rhizome of the Indian spice turmeric, has neuroprotective and antioxidant effects through activation of the transcription factor Nrf2, promotion of neurite outgrowth, and proliferation of neural stem cells via activation of the ERK and MAP kinase pathways [178–180]. Recently, researchers reported curcumin-encapsulated biodegradable poly(lactic-co-glycolic acid) nanoparticles that can induce neural stem cell proliferation and neuronal differentiation by neurogenesis [181]. Curcumin-loaded nanoparticles were developed by encapsulating curcumin in PLGA nanoparticles using the emulsion method. The nanoparticles have a mean diameter of 200 ± 20 nm and entrapment efficiency of 77%, leading to the increased water solubility of curcumin. Moreover, these nanoparticles increased neuronal differentiation by activating the Wnt/β-catenin pathway and reversed learning and memory impairments in an amyloid beta-induced rat model with AD-like phenotypes compared to free curcumin. These results could be ascribed to the localization of curcumin-loaded nanoparticles in the hippocampus across the blood-brain barrier.

Accumulation of amyloid-β (Aβ) in the brain has been implicated in the pathogenesis of Alzheimer’s disease. For this reason, a strategy for Aβ clearance is currently the primary therapeutic target for treating Alzheimer’s disease [177,182]. It was reported that α-mangostine, a polyphenolic xanthone derivative from mangosteen tree, upregulated low-density lipoprotein receptor (LDLR) expression, leading to the increased water solubility of curcumin. Moreover, these nanoparticles increased neuronal differentiation by activating the Wnt/β-catenin pathway and reversed learning and memory impairments in an amyloid beta-induced rat model with AD-like phenotypes compared to free curcumin. These results could be ascribed to the localization of curcumin-loaded nanoparticles in the hippocampus across the blood-brain barrier.

Fig. 10. A) Nanoformulated α-mangostine (NP(α-M)) selectively enhanced LDLR expression in microglia B) rather than astrocytes. C). Seven-month-old APP/PS1 mice were treated daily with NP(α-M) at an α-M dose of 1 mg/kg intravenously via the tail vein for 4 weeks. CD11b and GFAP were used as markers of microglia and astrocytes, respectively. The scale bar represents 20 μm. NP(α-M) rescued memory deficits in SAMP8 mice. Seven-month-old SAMP8 mice were treated daily with α-M formulations at an α-M dose of 1 mg/kg intravenously via the tail vein for 4 weeks with age-matched SAMP8 and SAMR1 mice given saline as the negative and normal controls, respectively. D) Escape latency, *p < 0.05, **p < 0.01, ***p < 0.001, significantly different from that of the negative control by Student’s t-test. E) Number of times crossing the escape platform used to locate. F) Percentage of time spent in the quadrant of the escape platform used to locate. Adapted with permission [183]. Copyright 2017, Elsevier.

nanomedicines to treat RONS-associated diseases.
solution, the α-mangostine-encapsulated nanoparticles remarkably delayed the blood clearance of α-mangostine and improved biodistribution profiles in the blood, brain, and liver by 48.8-, 2.29-, and 9.22-fold, respectively. Moreover, these nanoparticles increased the clearance of Aβ and reduced Aβ deposition in the brain tissue, resulting in amelioration of neurological changes and neuroinflammatory responses in Alzheimer’s disease model mice via α-mangostine-mediated modulation of LDLR expression. These findings demonstrate that the nanoparticles-mediated LDLR modulation might offer an efficient disease-modifying therapy for Alzheimer’s disease by the improved biodistribution of α-mangostine.

BPCs can also treat Parkinson’s disease caused by dopaminergic neuron death in the substantia nigra [184]. Schisantherin A, a major active component isolated from Schisandra Chinensis (Turcz.) Baill. has been investigated as a potential hepatoprotective and neuroprotective agent [185,186]. To improve cellular uptake in the brain and prolong circulation in the bloodstream, researchers have developed schisantherin A-loaded PEG-PLGA nanoparticles [186]. These nanoparticles have a mean particle size of 70 ± 4 nm and exhibit high encapsulation efficiency (91%) and drug loading (28%). When the nanoparticles were orally administered, schisantherin A was released from the nanoparticles in a sustained manner for an extended period, resulting in enhanced bioavailability. FRET imaging using zebrafish demonstrated that the nanoparticles improved cross-barrier transportation and afforded a sustained drug release profile. In addition, these nanoparticles notably exerted strong neuroprotective effects in zebrafish and an MPP-induced SH-SY5Y cell injury model by activating the Akt/Gsk3β pathway. These studies demonstrated that BPC-NFs can be designed to target and deliver BPCs to brain disorders and treat neurodegenerative diseases.

4. Applications for phototherapy and imaging

Light has been used as a source for treating and imaging various diseases, such as psoriasis, vitiligo, and skin cancer [223]. Since our systematic understanding of photochemical and photophysical processes began in the last century, phototherapy has been used to treat many diseases, such as chelitis and cancers. Due to its high efficacy and minimal invasiveness, phototherapy has been used as a stand-alone treatment or combination treatment with traditional chemotherapy to produce synergistic effects [224–226]. Phototherapy can generally be divided into photodynamic therapy (PDT) and photothermal therapy (PTT). For phototherapy, light with a fixed wavelength should be used to activate photoactive molecules. In PDT, photosensitizers activated by visible light generate ROS to kill target cells. Photothermal agents convert photo-energy into thermal energy under light excitation, leading to the thermal ablation of target cells. Recently, various BPCs isolated from plants have been identified and used as alternatives to

---

Fig. 11. A) Schematic illustration of the process of imaging-guided therapy of HepG2 tumor in vivo by Sorafenib-loaded PEG-MNPs (SRF-MNPs). B) Representative decay-corrected coronal (top) and transaxial (bottom) small-animal PET images (upper layer) and overlaid CT (grey) and PET (color) images (bottom layer) of HepG2 tumor (region enveloped by white dotted line) acquired at 2, 4, and 24 h after tail vein injection of 64Cu-radiolabeled (70.0 ± 5.0 μCi) SRF-MNPs. C) PA images, ultrasound (US) images, and overlaid PA (green) and US images (grey) of HepG2 tumor (region enveloped by yellow dotted line) before and after tail vein injection of 200 μl of SRF-MNP (SRF: 10 mg kg⁻¹, MNP: 40 mg kg⁻¹) in living mice (excitation wavelength = 680 nm for PAI). D) Histological sections of tumor tissue with TUNEL staining (× 10). Nuclei are stained blue (DAPI staining, × 10), and apoptotic cells are stained green (TUNEL staining, × 10). The scale bar represents 100 μm. Adapted with permission [229]. Copyright 2015, Wiley Online Library.
conventional phototherapeutic agents in cancer therapy because of their low systemic cytotoxicity towards normal tissues and selective therapeutic action against diseased tissues [227]. This section introduces several plant-derived BPCs as agents for phototherapy, imaging, and their applications.

Melanin, a naturally occurring pigment in many organisms, has been extensively investigated as a biomarker for melanoma imaging and as a probe for molecular imaging [228]. In a recent report, researchers...
nanoparticles (Fig. 11). Through the search, researchers have developed ultrasmall PEG-functionalized melanin nanoparticles with high binding ability to drugs as an efficient drug carrier for imaging-guided therapy, biodegradability, intrinsic photoacoustic property, and chelating capability with Cu$^{2+}$, the in vivo biodistribution of nanoparticles was successfully monitored by photoacoustic and PET imaging. Furthermore, the nanoparticles showed long-term retention in a tumor, guaranteeing the gradual and efficient release of sorafenib from the nanoparticles in the tumors. Intravenously injected nanoparticles showed better therapeutic effects compared to free sorafenib. These results demonstrated the great potential of BPC-NFs for image-guided therapy.

Melanin also has multimodal functions for magnetic resonance imaging and photothermal therapy [165,166]. One report introduced melanin-based liposomes with a unique core/shell structure consisting of PEG as the shell and melanin as the core [102]. The liposomes showed high performance as a contrast agent for photoacoustic imaging and magnetic resonance imaging in tumor-bearing mice, guiding the therapeutic process. Furthermore, upon 808 nm laser irradiation, liposomes with high melanin encapsulation efficiency (>89%) exhibited a remarkable photothermal effect for the complete eradication of tumors in breast cancer-bearing mice, mitigating the potential toxicity of melanin at a high dose (100 mg/kg). Another report demonstrated that melanin extracted from natural sesame was used as a natural staining agent for sentinel lymph node mapping [230]. Liposomes containing melanin showed high accumulation in the SLNs of tumor-bearing mice. Moreover, intratumorally injected liposomes significantly suppressed tumor growth upon 808 nm laser irradiation. These results obtained from melanin-based NFs provide a new strategy for creating desirable theranostic agents with high biocompatibility and satisfactory theranostic performance.

Phophorbide A, the product of chlorophyll breakdown, was used as a photosensitizer to treat microbes. Due to the singlet oxygen generated from phophorbide A, erythromycin-loaded liposomes covalently conjugated with pullulan-phophorbide A conjugate exerted antimicrobial activity against P. acnes under a 671 nm laser irradiation [231]. In another study, phophorbide A-conjugated glycol chitosan nanoparticles acted as a theranostic agent for treating and imaging human colon cancer [232]. These nanoparticles, under aqueous conditions, maintained photo-inactivity and a quenched state by self-quenching effects. On the other hand, under intracellular reductive conditions, the nanoparticles rapidly recovered their photocactivity, exhibiting higher phototoxicity toward cells under laser irradiation. Furthermore, the in vivo biodistribution monitored by a non-invasive fluorescence imaging system indicated that phophorbide A-conjugated glycol chitosan nanoparticles exhibited prolonged circulation in the whole body and enhanced accumulation in tumor tissue compared with free phophorbide A after systemically administrated. Researchers have also fabricated berberine chloride with aggregation-induced emission characteristics as a theranostic agent for cancer cells and bacteria [235]. Given the emission peak at 530 nm when it forms aggregates and its mitochondria-targeting ability by the positively charged structure, berberine chloride was used as a fluorescence imaging agent for HeLa cells and gram-positive S. aureus. Moreover, berberine chloride ablated cancer cells more effectively than normal cells via the photodynamic therapy pathway. It exerted an excellent photodynamic antibacterial effect against gram-positive bacteria in vitro and in vivo under white light irradiation.

Hypericin-encapsulated NLCs have been studied to investigate the PDT efficacy of hypericin in human cervical carcinoma cells. The NLCs generated singlet oxygen under a 580 nm laser treatment, leading to remarkable phototoxicity towards the cells [234]. Hypericin was also encapsulated in SLNs, which showed cellular uptake increased by 30% and an improvement of 26% in phototoxicity compared with free hypericin [235]. In addition, liposomal and polymeric nanoparticle formulations containing curcumin derivatives have also been developed as photodynamic agents. These curcumin-loaded liposomes and nanoparticles exhibited a formulation-dependent selective photodynamic effect on human ovarian cancer cells and microbes (S. mutans, C. albicans, and methicillin-resistant S. aureus). The phototherapeutic effects of hypericin and curcumin are responsible for generating singlet oxygen species upon irradiation with visible light [236].

As described above, several BPCs with photophysical properties are classified as phototherapeutic agents, but numerous BPCs must still be explored (Fig. 12). Although the detailed photopharmacological effects of BPCs have only been investigated with selected BPCs, such as melanin, curcumin, hypericin, and berberine, the workflows for the isolation and property evaluation of new BPCs will further increase through the revolution of irradiation techniques using xenon lamps with precise monochromatic light or LEDs with narrow-band emission. These new applications will help to fight numerous human diseases through phototherapy and imaging.

5. Conclusions and perspectives

For millennia, phytochemicals have been a fruitful source for the development of successful drugs. They are recognized as a crucial pool of pharmacologically active compounds that have been used to derive many blockbuster drugs. Progress in phytochemical-based drug discovery has also led to advancements in technologies for identifying and characterizing natural products. However, the pharmaceutical applications of BPCs have been clinically limited due to their poor solubility, instability, low bioavailability, off-targetability, and consequent toxicity after administration. With advances in nanotechnology, NF strategies have been used as an alternative approach to address these inherent problems. NF strategies in pharmaceutical applications have played an essential role in i) increasing the water solubility of lipophilic BPCs, ii) improving the chemical stability of BPCs under physiological conditions, iii) preventing the aggregation of BPCs, iv) enhancing the bioavailability of hydrophilic BPCs to transport across lipid-rich biological membranes, v) facilitating targeted delivery to the desired site, and vi) sustained and stimuli-responsive release of BPCs. For example, the therapeutic and diagnostic potential of BPCs have been greatly improved through NFs based on liposomes, lipid nanoparticles, phytosomes, and organic/inorganic nanoparticles. Because the physicochemical properties of BPCs, such as molecular weight, water solubility, hydrophobicity (log p), and the number of ring structures, vary significantly, suitable nanocarriers and formulation techniques should be selected for matching with BPC properties. Many BPCs with therapeutic potential have been approved for clinical use in many countries or are under clinical study. Moreover, dozens of nanoformulated BPCs are currently in clinical trials. With increasing interest in nanomedicine and the clarification of nanotechnology-specific medical regulations, BPC-NFs are expected to help overcome the drawbacks of BPCs in providing safer and more efficacious clinical treatment options.

NF strategies can also facilitate the repurposing of BPCs. Drug development is a challenging process that requires enormous costs and long-term investment with a high risk of failure. To reduce time-to-market, development costs, and risk, investigators and scientists have proposed alternative approaches. Above all, drug repurposing has become a mainstream strategy for reducing the chance of failure in drug development [283]. Drug repurposing is the process of identifying a new drug for a new therapeutic indication.
| Natural compound   | Natural resource                        | Solubility (logP) | Biological activity                                           | Refs       |
|--------------------|-----------------------------------------|-------------------|-------------------------------------------------------------|------------|
| Allicin            | Garlic                                  | 2.02              | Antimicrobial, anticancer                                    | [237]      |
| Apigenin           | Parsley, celery, celeriac, chamomile tea | 2.71              | Antimicrobial, anticancer                                    | [238]      |
| Arborinine         | Herbs, spices (Ruta graveolens)         | 3.15              | Anticancer                                                  | [239]      |
| Baicalein          | Roots of Scutellaria baicalensis and Scutellaria interflora | 2.71 | Antioxidant, anti-inflammatory                               | [240, 241] |
| Berberine          | Berberis                                | ~1.3              | Antiarrhythmic action, anti-inflammatory, antiangiogenic     | [145, 298] |
| Betulin            | Bark of birch trees                     | 6.17              | Anticancer                                                  | [196]      |
| Bixin              | Annatto                                 | 5.53              | Apoptotic, antioxidant                                      | [242, 243] |
| Boswellic acid     | *Scutellaria*                           | 2.71              | Antioxidant, anti-inflammatory                               | [244]      |
| Celastrol          | *Scutellaria*                           | 3.33              | Antioxidant, anti-inflammatory                               | [187, 245] |
| Chelerythrine      | Chelidonium majus, *Zanthoxylum clava-herculis* | ~0.88 | Antioxidant, anti-inflammatory                               | [246]      |
| Cinnamaldehyde     | Bark of cinnamon trees                  | 1.98              | Antioxidant, anti-inflammatory                               | [247]      |
| Curcubitacin E     | Curcubitaceae                           | 3.48              | Antioxidant, anti-inflammatory                               | [248]      |
| 15,16-Dihydrotanshinone I | *Salvia miltiorrhiza*                      | ~               | Antioxidant, anti-inflammatory                               | [189, 249] |
| Hesperetin         | Peppermint, lemon, sweet orange         | 2.68              | Antioxidant, anti-inflammatory, anti-allergic, anticarcinogenic | [250]      |
| Hydroxytyrosol     | Extra virgin olive oil                   | 0.89              | Antioxidant, anti-inflammatory, cancer preventive            | [251]      |
| Imperatorin        | Parsnips, lovages, parsley              | 3.15              | Antioxidant, anti-inflammatory, antiallergic                | [252]      |
| Kaempferol         | Plants (Pteridophyta, Pinophyta, Angiospermae) | 2.46 | Anticancer                                                  | [253]      |
| Luteolin           | Celery, broccoli, green pepper, parsley | 2.4               | Antioxidant, anti-inflammatory, chemopreventive             | [254, 255] |
| Madecassoside      | *Centella asiatica*                     | ~1.8              | Antioxidant, skin hydrating                                 | [101, 256] |
| α-Mangostin        | Mangosteen tree (*Garcinia mangostana*) | ~               | Antioxidant, anti-inflammatory, anticancer                  | [257]      |
| Melanin            | Chestnut shell                          | ~0.27             | Antioxidant                                                 | [258]      |
| Morin              | Osage orange, guava, bilberry           | 2.16              | Antioxidant, anti-inflammatory, cancer preventive            | [259]      |
| Naringenin         | Grapefruit, bergamot, sour orange       | 2.84              | Antioxidant, free radical scavenger, anti-inflammatory       | [260]      |
| Oleuropein         | Green olives, olive leaves, organ oil   | 0.11              | Antioxidant, anti-inflammatory, cancer preventive            | [261]      |
| Oxyresveratrol     | *Arctocarpus* laktoscha, white mulberry | 0.83 | Antioxidant, potent tyrosinase inhibitor                     | [262]      |
| Paenoil            | Peonies (*Paeonia suffruticosa*)         | 1.72              | Antioxidant, anti-inflammatory                              | [263]      |
| Pheophorbide       | Plants with chlorophyll                 | ~3.43, 2.62       | Photosensitizer, therapeutic                                 | [264]      |
| Rosmarinic acid    | Rosemary, mint, sage, thyme, lemon balm | 3.00              | Antioxidant, anti-inflammatory, osteoarthritis pain reduction | [265]      |
| Rutin              | Citrus fruit                            | ~0.87             | Preventive effect of blood clotting                          | [266]      |
| Salidroside        | *Rhodiola rosea*                        | ~0.58             | Antidepressant, anxiolytic                                  | [267]      |
| Sanguinarine       | *Sanguinaria canadensis*                | ~0.94             | Antifungal, anticarcinogenic                                 | [268]      |
| Schisantherin A    | *Schisandra chinensis*                  | 4.9               | Antiparkinsonian, anti-inflammatory                          | [269]      |
| Scutellarin        | *Scutellaria barbata*                   | ~               | Antitumor                                                   | [270]      |
| Shikonin           | *Lithospermum erythrorhizum*            | 2.12              | Antibacterial, anti-inflammatory, anticancer                | [271]      |
| Sinigrin           | Brassica vegetables                     | ~3.2              | Anticancer, antibacterial, antioxidant                      | [272]      |
| β-sitosterol       | Wheat germ, rice bran, flax seeds, peanuts, soybeans | 7.84 | Cholesterol-lowering                                        | [273]      |
| Syringic acid      | *Ardisia elliptica*                     | 1.01              | Antioxidant                                                 | [274]      |
| Tanshinone I       | Herbs (*Salvia miltiorrhiza Bunge*)     | 4.00              | Antioxidant, neuroprotective                                 | [275]      |
| Taxifolin          | Wood (Siberian larch), cloudberry, macadamia nut | 1.82 | Antioxidant, anti-inflammatory, cardiovascular, hepatoprotective | [276]      |
| Tetramethylpyrazine | Natto, fermented cocoa bean            | 0.063             | Anti-inflammatory, antiplatelet                             | [277]      |
| Root of Radix stephania tetrandrae | ~               | 6.48              | Anti-inflammatory, anticancer                               | [278]      |

(continued on next page)
use of an existing drug with an indication outside the range of its initial indication. This includes new therapeutic uses for already known drugs (repositioning) and different formulations of the same drug (reformulation). The repurposing of old drugs can shorten development time and reduce costs and risks for pharma because drug repurposing commonly starts with pre-tested compounds at a satisfactory level of safety and human tolerability.

Researchers in pharmaceutics and nanotechnology consider using nanof ormulation techniques for the reformulation of BPCs with poor solubility, stability, and undesirable toxicity. This allows BPCs to gain a wide therapeutic window through targeted delivery and their controlled release. As shown in Table 5, phytochemical BPCs have been widely explored, and their potent biological activities have been unveiled. Reformulating potential BPCs with NF techniques can improve solubility, stability, and bioavailability while avoiding side effects. Moreover, indications of BPCs formulated with NFs can be extended to various diseases beyond the primary drug indication. In this regard, NF techniques may guide advancements in drug repurposing.

When considering repurposing BPCs, the rational selection of proper types of nanocarriers depending on the physicochemical properties of BCPs is imperative. In this regard, researchers or pharmaceuticals should have an in-depth understanding of the intrinsic characteristics of nanocarriers. For instance, liposomes are suitable for encapsulating hydrophilic BPCs or their derivatives in their hydrophilic inner core. Although they can also load hydrophobic molecules in the lipid bilayers, the encapsulation efficiency and capacity are limited. In particular, hydrophobic BPCs with bulky chemical structures and large molecular weight are not good candidates for liposomes.

On the other hand, self-assembled polymeric nanoparticles or micelles can only incorporate hydrophilic BPCs, not hydrophobic ones. Those types of NFs also have concerns about their long-term stability, low BPC loading efficiency/capacity, and unwanted burst release. Meanwhile, relatively low biodegradability and long-term organ toxicity are the concerns about the inorganic nanocarriers. Overall, the short shelf-life and high production costs of BPC-NFs remain the critical drawbacks to be addressed.

Furthermore, despite the considerable advancement of NF techniques for BPCs, the clinical use of BPC-NFs to date is still impeded due to the following issues. Standard protocols for the physico-biochemical characterization of BPC-NFs, including safety and toxicity, are still lacking. Various factors, such as size, shape, surface properties, BPC release profiles, stability, and interactions with biological systems, should be fully characterized for clinical use of the BPC-NFs. Moreover, although several BPC-NFs are already approved for clinical use, the specific regulatory guidelines for approval processes for certain types of BPC-NFs are still lacking, hampering their clinical applications. Therefore, significant efforts should be dedicated to coming up with standard characterization protocols and specific regulations for the clinical use of BPC-NF.

Overall, emerging NF strategies for BPCs can play a pivotal role in the development of next-generation drugs for extended therapeutic applications. Therefore, great efforts are required from researchers and industry to develop various NF techniques and optimize them to maximize human healthcare benefits. In doing so, there is a significant opportunity to take BPC-NFs from bench to bedside and make a meaningful clinical impact with rational design.

CRediT authorship contribution statement

Hwa Seung Han: Conceptualization, Investigation, Writing – original draft. Song Yi Koo: Investigation. Ki Young Choi: Conceptualization, Funding acquisition, Project administration, Writing – original draft, Supervision.

Declaration of competing interest

The authors have no competing interests to declare.

Acknowledgments

This research was supported by Basic Science Research Programs through the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (2017R1D1A1B0304888, 2021R1A6A3A01086719 and 2015R1A6A3A04059033) and a Korea Institute of Science and Technology (KIST) intramural research grant.

References

[1] J.W.H. Li, J.C. Vederas, Drug discovery and natural products: end of an era or an endless frontier? Science 325 (2009) 161–165.
[2] R. Shen, A new golden age of natural products drug discovery, Cell 163 (2015) 1297–1300.
[3] A.L. Harvey, R. Edrada-Ebel, R.J. Quinn, The re-emergence of natural products for drug discovery in the genomics era, Nat. Rev. Drug Discov. 14 (2015) 111–129.
[4] J.K. Borchardt, The beginnings of drug therapy: ancient mesopotamian medicine, Drug News Perspect. 15 (2002) 187–192.
[5] B. Sandhya, S. Thomas, W. Isabel, R. Shentagararaih, Ethnomedicinal plants used by the valaiyan community of piranmalai hills (reserved forest), tanjilabad, India. A pilot study, Afr. J. Tradit., Complementary Altern. Med. 3 (2006) 101–114.
[6] C. Veeresham, Natural products derived from plants as a source of drugs, “J. Adv. Pharm. Technol. Research” (JAPTR)” 3 (2012) 200–201.
[7] F. Cos, A.J. Vlietinck, D.V. Berge, L. Maes, Anti-infective potential of natural products: how to develop a stronger in vitro ‘proof-of-concept’, J. Ethnopharmacol. 106 (2006) 290–302.
[8] J.J. Kellogg, D.A. Todd, J.M. Egan, H.A. Raja, N.H. Oberlies, O.M. Kvalheim, N. B. Czech, Biochemometrics for natural products research: comparison of data analysis approaches and application to identification of bioactive compounds, J. Nat. Prod. 79 (2016) 376–386.
[9] C. Katiyar, A. Gupta, S. Kanjilal, S. Katiyar, Drug discovery from plant sources: an integrated approach, Ays 53 (2012) 10–19.
[10] N.V. Yanishlieva, E. Marinova, J. Pokorný, Natural antioxidants from herbs and spices, Eur. J. Lipid Sci. Technol. 108 (2006) 776–793.
[11] M. Gordaliza, Natural products as leads to anticancer drugs, Clin. Transl. Oncol. 9 (2007) 767–776.
[12] S.L. Albarrancin, B. Stab, Z. Casas, J.J. Sutachan, I. Samudio, J. Gonzalez, L. Gonzalez, F. Capani, L. Morales, G.E. Barroto, Effects of natural antioxidants in neurodegenerative disease, Nutr. Neurosci. 15 (2012) 1–9.
[13] M.G. Moloney, Natural products as a source for novel antibiotics, Trends Pharmacol. Sci. 37 (2016) 689–701.
[14] D.J. Newman, G.M. Cragg, Natural products as sources of new drugs over the 30 Years from 1981 to 2010, J. Nat. Prod. 75 (2012) 311–335.
[15] T. Vasconcelos, B. Sarmento, P. Costa, Solid dispersions as strategy to improve bioavailability of poor water soluble drugs, Drug Discov. Today 12 (2007) 1068–1075.
[16] S. Kalepu, V. Nekkanti, Insoluble drug delivery strategies: review of recent advances and business prospects, Acta Pharm. Sin. B. 5 (2015) 442–453.
[17] K.T. Savjani, A.K. Gajjar, J.K. Savjani, Drug solubility: importance and advances and business prospects, ISRN Pharm (2012) 1–10, 2012.
[18] S. Thilakarathna, H. Rupasinghe, Flavonoid bioavailability and attempts for bioavailability enhancement, Nutrients 5 (2013) 3367–3387.
[19] C. Manach, G. Williamson, C. Morand, A. Scalbert, C. Rémésy, Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies, Am. J. Clin. Nutr. 81 (2005) 2305–2325.
H.S. Han et al.

Bioactive Materials 14 (2022) 182–205

[190] R. Rezaei-Sadabad, A. Eidi, N. Zarghami, A. Barzegar, Intracellular ROS protection efficiency and free radical-scavenging activity of quercetin and quercetin-encapsulated liposomes, Artificial Cells, Nanomed., Biotechnol. 44 (2016) 128–134.

[191] L. Mielczarek, P. Krug, M. Mazur, M. Milczarek, Z. Chilimonczyk, K. Wiktorska, In the triple-negative breast cancer MDA-MB-231 cell line, sulforaphane enhances the mitochondrial apoptosis and antiinvasion action of doxorubicin encapsulated in liposomes, Int. J. Pharm. 558 (2019) 311–318.

[192] J. Tian, L. Wang, L. Wang, X. Ke, A wogonin- loaded glycyrrhetinic acid-modified liposome for hepatic targeting with anti-tumor effects, Drug Deliv. 21 (2014) 553–559.

[193] Y.-J. Tsai, B.-H. Chen, Preparation of catechin extracts and nanoemulsions from green tea leaf waste and their inhibition effect on prostate cancer PC-3, Int. J. Pharm. 486 (2015) 1926.

[194] M. Najlah, A. Kadam, K.-W. Wan, W. Ahmed, K.M.G. Taylor, A.M.A. Elhissi, Novel paclitaxel formulations solubilized by parental route nutriment nanoemulsions for application against glioma cell lines, Int. J. Pharm. 506 (2016) 102–109.

[195] J. Pham, A. Nayel, C. Haung, T. Elbayoumi, Enhanced effectiveness of tocotrienol-based nano-emulsified system for topical delivery against skin carcinomas, Drug Deliv. 23 (2016) 1514–1524.

[196] R. Yadav, D. Kumar, A. Kumari, S.K. Yadav, PLA nanovehicles with encapsulated betulin: plant leaf extract-synthesized nanovesicles are more efficacious than PVA-synthesized nanovesicles, Biotechnol. Lett. 38 (2016) 259–269.

[197] E. Gulec, M. Thaiq, F. Khaja, A. Uzminis, H. Oynuksel, Curcumin in VIP-targeted sterically stabilized phospholipid nanocapsules: a novel therapeutic approach for breast cancer and breast cancer stem cells, Drug Deliv. Transl. Res. 3 (2013).

[198] F. Yang, W. Xiao, X. Ma, R. Huang, R. Yu, G. Li, X. Huang, C. Chen, P. Ding, Optimization of a novel chelerythrine-loaded magnetic Fe3O4/chitosan alpha-ketoglutamic acid system and evaluation of its anti-tumour activities, J. Pharm. Pharmacol. 68 (2016) 1040–1046.

[199] J. Luo, X. Meng, J. Su, H. Ma, W. Wang, L. Fang, H. Zheng, Y. Qin, T. Chen, Bioinmodified polyacetic-co-glycic acid nanocarriers with improved antiinflammatory activity of 15,16-dihydroxybenzole in human cervical cancer cell lines, Int. J. Agric. Food Chem. 66 (2018) 9219–9230.

[200] L. Mary, B. Sadhasivam, K. Palaniyandi, T. Muthuswamy, I. Ramachandran, J.C. Chamcheu, I.A. Siddiqui, V.M. Adhami, S. Esnault, D.J. Bharali, A. A.S. Haron, S.S. Syed Alwi, L. Saiful Yazan, R. Abd Razak, Y.S. Ong, F.H. Zakarial, Y.S. Ong, L. Saiful Yazan, W.K. Ng, R. Abdullah, N.M. Mustapha, S. Sapuan, J.B. Foo, Y.S. Tor, R. Rezaei-Sadabady, A. Eidi, N. Zarghami, A. Barzegar, Intracellular ROS B12-modified amphiphilic chitosan derivatives to treat type II diabetes induced-Guinea pig skin, Int. J. Nanomed. (2014) 1897.

[201] Q. Liang, J.-Q. Gao, Sequential release of salidroside and paeonol from a Hexadecyl-Dextran entrapped berberine nanoparticles abrogate high glucose carrier in BALB/c mice, Int. J. Nanomed. 11 (2016) 5905.

[202] R.P. Singh, H.V. Gangadharappa, K. Murutbunjaya, Phytosome complexed with chitosan for gingival delivery of silver and doxorubicin for infection in vitro, and in vivo evaluation, Eur. J. Pharmaceut. Sci. 122 (2018) 214–229.

[203] N. Ahmad, R. Ahmad, M.A. Alam, F.J. Ahmad, Quantification and brain targeting of eugenol-loaded surface modified nanoparticles through intranasal route in the treatment of cerebral ischemia, Drug Res. 68 (2018) 584–595.

[204] L. Li, Y. Wang, R. Guo, S. Li, J. Ni, S. Gao, X. Gao, J. Mao, Y. Zhu, P. Wu, H. Wang, D. Kong, H. Zhang, M. Zhan, G. Fan, Ginzenside Rg3-loaded, reactive oxygen species-responsive polymeric nanoparticles for alleviating myocardial ischemia-reperfusion injury, J. Contr. Release 317 (2020) 259–272.

[205] B.H. Jami, N.M. Mohaideen, A. Khan, S. Kaur, A. Rekha, N. Aditya, M. Shah, S.S. Ramakrishna, J. Balamuralidhar, J. Pruthi, S. Goyal, D. Rana, A. Gupta, S. Mathur, Hybrid nanoparticles loaded with rufin for effective brain delivery – comparative study with the gold standard ( Tween 80): optimization, characterization and biodistribution, Drug Deliv. 24 (2017) 1874–1890.

[206] R. Ackroyd, C. Kety, J. Zavada, The history of photodetection and photodynamic therapy, Photochem. Photobiot. 74 (2007) 656–669.

[207] H.S. Han, K.Y. Choi, H. Lee, M. Lee, J.Y. An, S. Shin, S. Kwon, D.S. Lee, J.H. Park, Gold-nanoclustered hyaluronan nano-assemblies for photothermally maneuvered photodynamic tumor ablation, ACS Nano 10 (2016) 10858–10868.

[208] S.I. Abdelwahab, B.Y. Sheikh, M.M. Taha, C.W. How, R. Abdullah, U. Yagoub, Enhanced therapeutic benefit of quercetin-loaded liposomal nanoparticles in a characterized rat, Chem. Biol. Interact. 271 (2017) 30–38.

[209] Q. Sun, W. Li, H. Li, X. Wang, Y. Wang, X. Niu, Preparation, characterization and anti- ucer efficacy of sanguinarine loaded solid lipid nanoparticles, Pharmcoloy 100 (2017) 14–24.

[210] R.P. Singh, H.V. Gangadharappa, K. Murutbunjaya, Phytosome complexed with chitosan for gingival delivery of silver and doxorubicin for infection in vitro, and in vivo evaluation, Eur. J. Pharmaceut. Sci. 122 (2018) 214–229.

[211] A.i. Abd El-Fattah, M.M. Fatby, Z.Y. Ali, A.E.A. El-Garawany, E.K. Mohamed, Enhanced therapeutic benefit of quercetin-loaded liposome nanoparticles in a characterized rat, Chem. Biol. Interact. 271 (2017) 30–38.

[212] S.I. Abdelwahab, B.Y. Sheikh, M.M. Taha, C.W. How, R. Abdullah, U. Yagoub, Enhanced therapeutic benefit of quercetin-loaded liposome nanoparticles in a characterized rat, Chem. Biol. Interact. 271 (2017) 30–38.
